Evaluating traditional Chinese medicine modulation of the gut microbiota–bile acid axis in metabolic and inflammatory diseases: mechanistic evidence and translational priorities
- 1Qingdao Central Hospital, University of Health and Rehabilitation Sciences
- 2Qingdao Special Service Sanatorium of PLA Navy
- 3Shandong University of Traditional Chinese Medicine Affiliated Hospital
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, type 2 diabetes mellitus (T2D), and inflammatory bowel disease (IBD) are clinically distinct disorders that share perturbations in intestinal ecology, bile-acid composition, epithelial barrier function, and immune-metabolic regulation. Traditional Chinese medicine (TCM) may modify these interconnected processes, but the translational significance of reported effects remains uncertain. Changes in microbial composition are often interpreted as mechanisms without evidence of altered microbial function, bile-acid profiles or concentrations, receptor engagement, or clinical benefit. Here, we present a structured narrative review that uses the gut microbiota-bile acid axis to evaluate TCM in metabolic and inflammatory disease. We describe how microbial bile salt hydrolases, the bile acid-inducible ( bai ) operon, hydroxysteroid dehydrogenases, and amino-acid conjugation diversify the bile-acid pool and influence farnesoid X receptor (FXR), Takeda G protein-coupled bile acid receptor 1 (GPBAR1, also known as TGR5), and immune pathways. We then assess evidence for defined TCM constituents and formulae in MASLD, obesity/T2D, and IBD. Across these settings, the most informative studies combine a standardized intervention with longitudinal metagenomic and targeted bile-acid profiling, host-signaling measurements, and an outcome that is attenuated by microbiota depletion, fecal microbiota transplantation, or functional microbial manipulation. Only one eligible human trial, of Qushi Huayu in adults enrolled under the historical NAFLD designation, reported both clinical and microbiota-related outcomes. Evidence for obesity/T2D and IBD was predominantly preclinical or observational, and the framework is therefore a translational assessment tool rather than a clinically validated model. We therefore propose an evidence hierarchy and a minimum translational package that integrates chemical quality control, dietary and co-medication assessment, strain- and gene-resolved microbiome analysis, targeted bile-acid metabolomics, and pathway-directed validation. TCM should be considered a potential precision adjunct to standard care only when reproducible microbial-metabolic phenotypes are linked to clinically meaningful benefit.
Related
- Microbiota–host crosstalk in ulcerative colitis: mechanistic evidence and translational prospects for traditional Chinese medicine
- Modulation of microbiota by traditional Chinese medicine in chronic inflammatory airway disease: a systematic review and meta-analysis of animal studies
- Dynamic three-dimensional chromatin remodeling in lung disease: mechanistic principles, pathogenic regulatory networks, and translational challenges
- Natural Products in Anticancer Activity: 2nd Edition—From Chemical Diversity to Mechanistic and Translational Insights
- Target Discovery and Drug Intervention in Inflammatory Diseases： A Paradigm Shift from Mechanistic Dissection to Precision Therapy
BibTeX
@article{yu2026evaluating,
title = {{Evaluating traditional Chinese medicine modulation of the gut microbiota–bile acid axis in metabolic and inflammatory diseases: mechanistic evidence and translational priorities}},
author = {Yanyan Yu and Jian Wang and Qingbao Yuan and Linghui Yu and Chunling Zhang},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1977691},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1977691/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Evaluating traditional Chinese medicine modulation of the gut microbiota–bile acid axis in metabolic and inflammatory diseases: mechanistic evidence and translational priorities
AU - Yanyan Yu
AU - Jian Wang
AU - Qingbao Yuan
AU - Linghui Yu
AU - Chunling Zhang
PY - 2026
DA - 2026/10/13
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1977691
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1977691/full
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, type 2 diabetes mellitus (T2D), and inflammatory bowel disease (IBD) are clinically distinct disorders that share perturbations in intestinal ecology, bile-acid composition, epithelial barrier function, and immune-metabolic regulation. Traditional Chinese medicine (TCM) may modify these interconnected processes, but the translational significance of reported effects remains uncertain. Changes in microbial composition are often interpreted as mechanisms without evidence of altered microbial function, bile-acid profiles or concentrations, receptor engagement, or clinical benefit. Here, we present a structured narrative review that uses the gut microbiota-bile acid axis to evaluate TCM in metabolic and inflammatory disease. We describe how microbial bile salt hydrolases, the bile acid-inducible ( bai ) operon, hydroxysteroid dehydrogenases, and amino-acid conjugation diversify the bile-acid pool and influence farnesoid X receptor (FXR), Takeda G protein-coupled bile acid receptor 1 (GPBAR1, also known as TGR5), and immune pathways. We then assess evidence for defined TCM constituents and formulae in MASLD, obesity/T2D, and IBD. Across these settings, the most informative studies combine a standardized intervention with longitudinal metagenomic and targeted bile-acid profiling, host-signaling measurements, and an outcome that is attenuated by microbiota depletion, fecal microbiota transplantation, or functional microbial manipulation. Only one eligible human trial, of Qushi Huayu in adults enrolled under the historical NAFLD designation, reported both clinical and microbiota-related outcomes. Evidence for obesity/T2D and IBD was predominantly preclinical or observational, and the framework is therefore a translational assessment tool rather than a clinically validated model. We therefore propose an evidence hierarchy and a minimum translational package that integrates chemical quality control, dietary and co-medication assessment, strain- and gene-resolved microbiome analysis, targeted bile-acid metabolomics, and pathway-directed validation. TCM should be considered a potential precision adjunct to standard care only when reproducible microbial-metabolic phenotypes are linked to clinically meaningful benefit.
SN - 1664-302X
ER -